

Accepted Manuscript

Title: Real time optical immunosensing with flow-through porous alumina membranes

Author: Jesús Álvarez Laura Sola Marina Cretich Marcus J. Swann Kristinn B. Gylfasson Tormod Volden Marcella Chiari Daniel Hill



PII: S0925-4005(14)00716-3
DOI: <http://dx.doi.org/doi:10.1016/j.snb.2014.06.027>
Reference: SNB 17041

To appear in: *Sensors and Actuators B*

Received date: 21-3-2014
Revised date: 27-5-2014
Accepted date: 8-6-2014

Please cite this article as: J. Álvarez, L. Sola, M. Cretich, M.J. Swann, K.B. Gylfasson, T. Volden, M. Chiari, D. Hill, Real time optical immunosensing with flow-through porous alumina membranes, *Sensors and Actuators B: Chemical* (2014), <http://dx.doi.org/10.1016/j.snb.2014.06.027>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

- First real time immunoassay within a free standing macroporous alumina membrane.
- Targeted delivering of analytes to bioreceptors immobilized on pore walls
- Fast sensing response times and small sample volumes (< 100 μ l).
- A novel two step procedure for a functional coating of DMA and NAS on AAO.
- The first time poly(DMA-NAS) coating has immobilized allergens on a porous surface.

Accepted Manuscript

Real time optical immunosensing with flow-through porous alumina membranes

Jesús Álvarez^a, Laura Sola^b, Marina Cretich^b, Marcus J. Swann^c, Kristinn B. Gylfasson^d, Tormod Volden^e, Marcella Chiari^b and Daniel Hill^{a*}

^aUnit of Optoelectronic Materials and Devices, Materials Science Institute, University of Valencia, Catedrático José Beltrán 2, 46980 Paterna, Valencia, Spain

^bIstituto di Chimica del Riconoscimento Molecolare, Consiglio Nazionale delle Ricerche, Via Mario Blanco, 9, 20146 Milano, Italy

^cFarfield Group Ltd, Biolin Scientific, 3000 Manchester Business Park, Aviator Way, Manchester, M22 5TG, United Kingdom

^dMicro and Nanosystems, KTH Royal Institute of Technology, Osquidas väg 10, 100 44 Stockholm, Sweden

^eCSEM SA, Central Switzerland Center, Untere Gründlistrasse 1, CH-6055 Alpnach

* Corresponding author: +34 963544857, daniel.hill@uv.es

Abstract: Through the presentation of analytical data from bioassay experiments, measured by polarimetry, we demonstrate for the first time a real time immunoassay within a free standing macroporous alumina membrane. The 200 nm nominal pore diameter of the membrane enables flow-through, thereby providing an ideal fluidic platform for the targeted delivery of analytes to bioreceptors immobilized on the pore walls, enabling fast sensing response times and the use of small sample volumes (< 100 μ l). For the immunoassay, the pore walls were first coated with the functional copolymer, copoly(DMA-NAS) using a novel coupling process, before immobilization of the allergen protein, β -lactoglobulin, by spotting. The immuno-assay then proceeded with the binding of the primary and secondary antibody cognates, rabbit anti- β -lactoglobulin and anti-rabbit IgG respectively. Through the use of streptavidin coated quantum dots as refractive index signal enhancers, a noise floor for individual measurements of 3.7 ng/ml (25pM) was obtained, with an overall statistical, or formal assay LOD of 33.7 ng/mL (225pM), for total assay time below one hour.

Index Terms: Porous alumina; Form birefringence; Polarimetry; Optical biosensing; copolymer; quantum dots.

1. Introduction

Due to an increasing demand for rapid, reliable and economical near patient or field testing, over the last few decades there has been a strong trend toward in-vitro point of care (PoC) testing in clinical diagnosis, food safety, environmental monitoring, safety and security [1, 2]. Significant segments of PoC testing are based on bioassays where extremely low concentrations of markers (infectious agents, pesticides, cardiac markers, allergens etc.) need to be identified and distinguished from other matter within small volumes of complex matrices (e.g. whole blood, sputum swabs, faeces, cell lysate...). To meet these needs, PoC in-vitro diagnostic devices are required to provide a fast, sensitive and selective analysis of assays, ideally a simultaneous analysis of multiple assays, and therefore new approaches being explored are often based on highly integrated sensors within a Lab on Chip format [3]. Furthermore, for low cost and practical application by non-technical users, optimal designs negate the need for lengthy off-chip sample preparation.

1 At the core of these devices is the biosensor [4] and those based on optical interrogation offer
2 important advantages such as: 1) non-invasive, safe and multi-dimensional (intensity, wavelength,
3 phase, polarization) detection; 2) well-established tools from communication and Micro-Nano
4 technologies (MNT) industries (lasers, detectors, waveguides) and 3) optical frequencies that
5 coincide with a wide range of physical properties of bio-related materials.

6 Many optical biosensors are based on refractive index (RI) sensing, where the effective refractive
7 index of the surface of an optical structure is modified by the presence of a target analyte [5]. For
8 the development of photonic biosensors, nanostructured materials like porous silicon (PSi) or
9 porous alumina (AAO) have gained special attention, as they have higher surface areas than
10 planar biosensors for capturing analytes and thus permit lower detection limits [6]. To date, several
11 label-free photonic biosensors have been successfully developed on both PSi [7, 8] and AAO [9,
12 10] porous membranes, using reflectometric interference spectroscopy (RIfS). However, this
13 approach produces slow responses and long sensing times, due to the narrow (<100nm) closed
14 end pores of the membranes used, resulting in analyte delivery being mainly governed by the
15 stationary flux produced by electrostatic interactions. The problem of analyte delivery has been
16 obviated in a fluorescent flow-through assay using a fibrous filter as an improved method for
17 protein capture [11], however this was as an ex-situ end point assay which after the analyte was
18 bound required the substrate to be dried and transferred to a reader for measurement under index
19 matched liquid. In a recent approach using optical polarimetry [12], we demonstrated that free
20 standing macroporous AAO membranes with 200nm diameter pores when functionalized with an
21 epoxysilane allow analytes to flow-through them. Due to the pore size, the analyte molecules flow-
22 through no more than 100 nm from the assay surface (the pore wall), breaking the mass transport
23 limitations and so effectively targeting their delivery, for real-time biosensing responses, an
24 approach which has also been proposed elsewhere with similar porous optical structures [13, 14].

25 Here, we report on the use of this approach for immunosensing, by coating the membrane with a
26 functional copolymer, copoly(DMA-NAS), through a novel procedure that has demonstrated less
27 non-specific binding, and therefore greater selectivity, and more stability over time for immobilized
28 allergens than epoxysilane [15]. In this paper, we first detail the procedure for immobilizing the
29 bioreceptors inside the pores of the alumina membrane, including the novel process for coating the
30 pores with the copolymer. After demonstrating the stability of the immobilized allergens, we show a
31 5 times signal enhancement through the use of streptavidin coated quantum dots (SA-QDs)
32 compared to the secondary antibody used. Finally, we show the concentration performance of the
33 immunoassay by using solutions of the first antibody at different concentrations, followed by a fixed
34 concentration of the secondary antibody and streptavidin coated quantum dots.

35 **2. Material and methods**

36 **2.1 Material**

37 The free-standing macroporous alumina membranes were purchased from Whatman (Anodisc™
38 membranes, 13 mm diameter, 200 nm nominal pore diameter, 60 μm thickness and 0.5 porosity)
39 and several were characterised morphologically by SEM to verify the approximate pore dimensions.
40 PBS (Phosphate buffered saline) tablets, Tween 20, toluene, dimethylformamide (DMF) *N,N*-
41 dimethylacrylamide (DMA), [3-(methacryloyl-oxy)propyl]trimethoxysilane (MAPS), tetrahydrofuran
42 (THF), azoisobutyronitrile (AIBN) and absolute ethanol, were acquired from Sigma-Aldrich (St. Louis,
43 MO, USA). *N*-acryloyloxysuccinimide (NAS) was synthesized as reported elsewhere [16].


44 The primary antibody employed rabbit anti-β-lactoglobulin, was purchased from Bethyl
45 Laboratories (Montgomery, TX, USA). Antigen protein β-lactoglobulin B, the secondary antibody,
46 biotinylated anti-rabbit IgG, and BSA (Bovine serum albumin), were purchased from Aldrich (St.
47 Louis, MO, USA). Streptavidin conjugated CdSe quantum dots (Qdot® 800 Streptavidin Conjugate)
48 were supplied by Invitrogen (Life technologies, NY, USA). All buffers were filtered through 0.2μm
49 filters before use.

1

2 **2.2 Bioreceptor immobilization**

3 One of the key factors for the development of optical biosensors for point-of-care diagnostic
 4 devices is the immobilization of the bioreceptors on the sensor surface in a way that retains a high
 5 degree of activity and low levels of non-specific binding. A polymeric coating introduced by Pirri and
 6 co-workers in 2004 [17] was shown to possess favorable characteristics for performing an optimal
 7 microarray analysis. This coating is obtained by adsorption on solid surfaces of a diluted aqueous
 8 solution containing a co-polymer, which provides a stable and hydrophilic film. This polymer,
 9 poly(DMA-NAS-MAPS) is obtained by random radical polymerization of three monomers: *N,N*-
 10 dimethylacrylamide (DMA), which self-adsorbs on glass by weak, non-covalent interactions with
 11 silanol groups, 3-(trimethoxysilyl)propyl methacrylate (MAPS), which stabilizes these interactions
 12 by the formation of stable, covalent bonds and *N*-acryloyloxysuccinimide (NAS), which represents
 13 the chemically reactive groups with the aim to bind biomolecules on the surface. Thanks to its
 14 monomer composition this copolymer provides a low fluorescence background for surfaces and a
 15 highly selective binding chemistry whilst retaining the native configuration of immobilized probes.
 16 This polymer has been previously demonstrated to immobilize allergens on different materials such
 17 as glass, nitrocellulose and silicon slides [18] and more recently on a SiO_xN_y Dual Polarization
 18 Interferometry chip [15] allowing the efficient measurement of their interactions with allergen-
 19 specific Immunoglobulin E (IgEs) in the complex matrix of serum, proving its suitability as a non-
 20 fouling coating and that it is robust to allergen storage.

21 For this work it was not possible to coat the surface with poly(DMA-NAS-MAPS) using the usual dip
 22 and rinse method, due to the instability of AAO towards some of the reagents used in the
 23 procedure, therefore, a functional coating of DMA and NAS was obtained via a novel two step
 24 procedure involving modification of the surface with MAPS followed by the *grafting* of poly(DMA-
 25 NAS) formed by in situ radical polymerization. This coating was used for the first time to immobilize
 26 allergen proteins on a porous surface.



27

28

29 **Figure 1. Scheme of the grafting process of poly(DMA-NAS) onto an AAO membrane**
 30 **silanized with MAPS that bears an allyl group which allows polymerization with DMA and**
 31 **NAS**

31

32

32 **2.2.1 Pore surface coating**

33

34

35

36

37

38

39

40

41

42

43

44

Before the pore surfaces were coated, the membranes were cleaned with an oxygen plasma for 10
 minutes in a Harrick Plasma cleaner (Ithaca, NY, USA) and then immersed in a solution of MAPS
 in toluene (10% v/v). A vacuum was applied for 10 minutes in order to assure that the pores were
 completely filled with this solution, before the reactor was sealed and left overnight at room
 temperature. After silanization, the membranes were first washed on a Buchner funnel, under
 vacuum with toluene and then with THF and finally cured under vacuum at 80°C for 30 minutes.
 Thereafter, a 20 mL solution of 10% DMA and NAS in DMF (molar ratio 90-10; 1.85 mL, 17.95 mM
 and 340 mg, 2.01 mM respectively) was prepared. The silanized membranes were then immersed
 in this solution and an argon purge was used to remove oxygen from the solution for 15 minutes.
 AIBN (6.5 mg, 2 mM) was then added and a vacuum applied for 10 minutes to assure that the
 pores were completely filled with the degassed monomer solution and then the reactor was sealed
 and heated with a silicon bath, at 65°C overnight. Finally, the membranes were washed on a


1 Buchner funnel, under vacuum, first with DMF and then with THF, before being dried under
2 vacuum at room temperature.

3 4 **2.2.2 Allergen immobilization**

5 The allergen β -lactoglobulin was spotted onto the coated membranes using a piezoelectric spotter
6 (Sciencion SciFlexArrayer S5). Several droplets of a solution of β -lactoglobulin (1mg/mL in PBS)
7 were spotted in the central area of the membranes so as to form a square of 5x5 mm. Membranes
8 were layered on nitrocellulose slides wetted with 10 μ L of the same antigen solution, so to assure
9 complete filling of the pores by capillary action. The spotted membranes were then left overnight in
10 a moisture chamber before being rinsed with PBS, on a Buchner funnel, and then treated with a
11 solution of BSA (0.1 mg/mL) to block any remaining active sites of the coating.

12 13 **2.3 Membrane transfer to supports**

14 After having immobilized the bioreceptors on the functionalized free-standing membranes, in order
15 to conduct flow-through sensing experiments, the circular membranes were first transferred onto
16 mechanical support chips (Figure 2). The support chips chosen were 15 by 15 mm pieces of single
17 side polished silicon wafer, 500 μ m thick, due to their stability in an aqueous environment as well
18 as the flat interface they provide for a good mechanical contact between them and the membranes.
19 The support chips had a 750 μ m diameter opening in the centre which was made using a CO₂ laser,
20 and the edges were chamfered on the reverse side in order to allow the laser light to readily pass
21 through the hole without being occluded by the walls of the support chip. A 1 μ m thick layer of
22 PMMA (Poly(methyl methacrylate)) resist was used as the adhesion layer between the alumina
23 membranes and the silicon supports. Support mounted membranes were then stored in a
24 desiccator at 4 °C until they were used in the biosensing experiments. This set-up forms a 750 μ m
25 diameter active spot area and is compatible with a multispot format which would allow multiplexed
26 assays. Smaller spots are also possible as the measurement sensitivity is in principle not spot
27 size dependent.




28
29 **Figure 2. Picture of a free standing membrane mounted on a silicon support.**

30 31 **2.4 Readout platform**

32 The readout platform (Figure 3a) used a polarimetric setup [19] to interrogate the changes in the
33 optical anisotropy of the macroporous free-standing membranes, the sensing mechanism for the
34 bioassay. Analyte molecules within the pores modify the birefringence which is detected within the
35 setup as a change of phase retardation between the components of light polarized along the main
36 axis directions. Briefly the setup is: the output light from a 980 nm laser diode is first collimated and
37 then directed to a linear polarizer with the resulting linearly polarized light then entering a
38 photoelastic modulator (PEM; Hinds Instruments PEM-100). The modulated light exiting the PEM is
39 then incident at 45° to the planar surface of the alumina membrane, which is mounted on the
40 support chip within a flow-cell. The light exiting the membrane, after passing a second polarizer, is
41 detected by a photodiode which is connected to a lock-in amplifier (SR-830). The lock-in amplifier
42 demodulates the detected signal extracting the amplitudes of its first and second harmonics, which
43 are related to the phase retardation.


1 The fluidic setup used within the readout platform allows the analytes to be pumped through the
 2 flow cell encased and mechanically supported membrane by use of a pressure controller
 3 connected to a syringe where the running buffer is stored (Figure 3b). Before filling with liquid, the
 4 system is purged with CO₂ for 5 minutes to ensure complete filling and to reduce the incidence of
 5 bubbles. The purging consists of the CO₂ displacing the air in the system and any that is not
 6 displaced on filling with solution is then dissolved in the water or buffer.



7
 8 **Figure 3. (a) Layout of the optical polarimetric readout platform used for measuring the phase**
 9 **retardation within the membranes. (b) Scheme of fluidic setup integrated within a flow-cell where**
 10 **the mounted membrane is placed and whose inlet port is connected to a pressure controller**
 11 **providing a constant pressure flow.**

12 13 2.5 Immunosensing experiments

14 After mounting a membrane with immobilized allergen into the flow-cell and purging with CO₂, a
 15 running buffer of PBS-T (PBS, 0.02% (v/v) Tween 20) was introduced for 15 minutes before the
 16 behaviour of the immobilized allergen was tested by injecting its cognate antibody rabbit anti- β -
 17 lactoglobulin. The membrane was then rinsed again with the running buffer and the secondary
 18 antibody anti-rabbit-IgG (biotinylated) was then introduced into the system followed by streptavidin
 19 conjugated quantum dots (SQ-QD) as signal enhancers, which increased the sensitivity for low
 20 concentrations of the primary antibody. A schematic representation of this bioassay is depicted in
 21 Figure 4.



22
 23 **Figure 4. The immunoassay carried out in a macroporous alumina membrane. β -lactoglobulin**
 24 **protein was used as the immobilized antigen for the detection of rabbit anti- β -lactoglobulin.**
 25 **Biotinylated secondary antibody (anti-rabbit-IgG) and streptavidin coated CdSe quantum dots**
 26 **were used to increase the signal produced by the primary antibody.**

3. Results and discussion

3.1. Characterization of AAO membranes

The membranes were analyzed by FT-IR after each step of the coating process, to confirm that the chemical modification was taking place as intended. The signals from uncoated membranes (blank samples) were subtracted from the spectra of modified membranes (using Spectra Manager software 1.52 from Jasco, MD, USA) so as to highlight the peaks corresponding to the coating reagents. The subsequent FT-IR spectra of the polymer coated membranes, Figure 5, show a peak around 1740 cm^{-1} corresponding to the stretching of carbonyl group of MAPS which increases when NAS is added onto the surface. On coated membranes, as well as the NAS peak, it is possible to observe a peak at 1640 cm^{-1} which corresponds to the stretching of the DMA carbonyl group. For comparison, an FT-IR (poly(DMA-NAS-MAPS)) was also recorded, so as to confirm the presence of the coating on the membrane.





Figure 5. FT-IR analysis of a functional polymer coated membrane. Peaks corresponding to DMA and NAS carbonyl moieties are easily observed when compared to an uncoated membrane.


3.3 Immunosensing results

The activity of the immobilized allergens was tested by running the immunoassay explained in Section 2.5. Figure 6 shows the measured phase retardation when concentrations of $1\text{ }\mu\text{g/mL}$ (6.7 nM) are used for the first and secondary antibody and a concentration of 2.5 nM is used for the SA-QD. After placing the alumina membrane in the flow-cell and prior to the antibody injections, the baseline obtained during the buffer rinse showed good stability which demonstrated that the antigen is stably immobilized on the polymer coated surface. After recording a stable baseline during six minutes we then injected the first antibody rabbit anti- β -lactoglobulin for a period of 10 minutes. Following a six minutes rinse with the running buffer the secondary antibody anti-rabbit IgG was then injected for 10 minutes. As the secondary antibody is polyclonal, a larger response is observed for this, compared to the binding of the initial primary antibody. After further rinsing, the SA-QDs were added as a signal enhancer at a concentration of 2.5 nM , which was sufficient to saturate the captured secondary antibodies. Due to the size of the SA-QDs an enhancement of 5 times is observed in the signal over the response produced by the secondary antibody.

After this experiment a series of experiments was run using 12 different membranes with the same immunoassay where the concentration of the first antibody was varied between 5 and 1000 ng/mL in order to estimate the detection limit of the system. Figure 7 (a) shows the overlaid response obtained for the different membranes.



1
2
3
4
Figure 6. A sensorgram showing the signal response due to the binding of the first and secondary antibodies, followed by the enhancement produced by the SA-QD.



5
6
7
8
9
10
11
a) Figure 7. (a) An overlay of the signal responses produced by the SA-QD when the concentration of the first antibody is increased from 5 ng/mL to 1000 ng/mL. (b) Phase retardation change upon injection of 2.5 nM SA-QD over biosensing experiments using a range of primary antibody concentrations (5-1000 ng/mL). The fitted line corresponds to a 1:1 binding model of K_D 228 ng/mL and R_{max} of 7.7 mrad.

12 In Figure 7 (b), we present the phase retardation change produced by the signal enhancement
13 quantum dots as a function of the concentration of the first antibody. The limit of detection of the
14 system was calculated according to the formula given in [20], which defines the analytical limit of
15 detection as the analyte concentration that can reliably be distinguished from the noise:

$$16 \quad LoD = LoB + 1.645 \cdot SD_{low_concentration_sample} \quad (1)$$

17 where $SD_{low_concentration_sample}$ corresponds to the standard deviation obtained from a series of
18 samples at low concentration and LoB is the limit of blank defined as the highest analyte
19 concentration value expected to be obtained for a sample containing no analytes. LoB is equal to:

$$20 \quad LoB = mean_{blank} + 1.645 \cdot SD_{blank} \quad (2)$$

1 Where $\text{mean}_{\text{blank}}$ corresponds to the mean value obtained from a series of blank samples and SD
2 corresponds to the standard deviation of the samples.

3 In our case, using β -lactoglobulin as the immobilized antigen, the limit of detection of our system
4 was 33.7ng/ml. This value is chiefly limited by the reproducibility of the mechanical setup rather
5 than the measurement signal noise level, which would establish a limit an order of magnitude lower,
6 at 3.7 ng/mL. For application in clinical allergy diagnostics, a measurement range of 0.84-240 ng/ml
7 (0.35-100 kU/L) is required by clinicians [21], and thus the presented proof-of-concept system
8 already shows relevant performance for this application. With improvements in the mechanical
9 design and further assay optimization, we expect to improve the detection limit to cover the full
10 range.

11 Compared to previous work employing porous membranes in a flow-over configuration, the flow-
12 through configuration applied here enables more efficient convective delivery of analytes to the
13 immobilized recognition molecules. This results in a short total assay time of below 60 minutes for
14 a sandwich assay employing both a secondary and tertiary binding, compared to flow-over assay
15 times of 5 hours for a two-step assay in [8]. Furthermore, in a flow-through configuration the entire
16 sample passes through the membrane in close proximity to the immobilized recognition molecules,
17 and hence the sample utilization is greatly improved. For example, the total analyte containing
18 sample volume consumed during the 10 minute injection in this work was 1 mL, while in [8] a total
19 volume of 50 mL was consumed (100 minute injection at a flow rate of 0.5 mL/min). In terms of
20 analyte mass consumed, the contrast is even more stark, i.e. 1 μg (1 mL of 1 $\mu\text{g}/\text{mL}$ Anti- β -
21 lactoglobulin solution) in flow-through, compared to 5 mg (50 mL of a 0.1 mg/mL IgG solution) in
22 flow-over [8]. This difference is particularly important for analysis of small and costly samples, such
23 as in neonatal diagnostics and drug development, respectively.
24

25 4. Conclusions

26 We have demonstrated for the first time a real time immunoassay within a free standing flow-
27 through macroporous alumina filter membrane, which provides a route towards rapid and low cost
28 biosensing.

29 Both the stability and the functionality of the coating and spotting procedure were evaluated by
30 injecting inside the pores the antibodies rabbit anti- β -lactoglobulin and anti-rabbit-IgG. The
31 response produced by the binding between the allergen protein and its cognate antibodies was
32 acquired in real-time, by using an optical polarimetric readout platform to measure the anisotropy
33 change of the macroporous alumina membrane.

34 Finally, the use of streptavidin conjugated CdSe quantum dots was investigated as refractive index
35 signal enhancers obtaining five-fold signal amplification compared with the signal produced by the
36 secondary antibody alone. Using this signal amplifier a noise floor for individual measurements of
37 3.7ng/ml (25pM) was obtained, with an overall statistical, or formal assay LOD of 33.7 ng/mL
38 (225pM), for total assay times of under one hour.
39

40 Acknowledgements

41 The authors would like to acknowledge the contributions from Geoff Platt (Farfield), Isabelle Metton
42 (Phylogene), Steven Sievers (Charité) and Thomas Stadelmann (CSEM) for their participating in
43 prior biosensing experiments that led up to this work. We also thank Helmut Knapp, Siegfried Graf
44 (both CSEM) for the design and fabrication of the flow cell and Wouter van der Wijngaart (KTH) for
45 fluidic discussions. Finally we thank Intenanomat for the use of their wet labs for reagent
46 preparation and storage. This work was carried out within the FP7-ICT-257401-POSITIVE project,
47 funded by the European Commission.
48

1 Vitae

2 **Jésus Álvarez Álvarez** has a Degree in Telecommunications Engineering from the Polytechnical
3 University of Valencia (UPV), with a final year project 'Design and Simulation of photonic sensors
4 based on resonant rings' in the FP6 SABIO project. He then successfully completed a Masters in
5 Technology, Systems and Communication Networks (UPV) with the thesis 'Modeling and
6 Assessing an Energy-Aware Power-Supply Wireless Sensor Nodes for the TUHH (Hamburg
7 University of Technology)'. In 2013 he successfully defended his PhD thesis 'Development of a
8 polarimetric based optical biosensor using a free standing porous membrane' at UMDO (University
9 of Valencia) from work performed in the FP7 Positive project.

10 **Laura Sola** received the M.S. degree in Chemistry and Pharmaceutical Techniques in 2008 and
11 the PhD in Drug Chemistry in 2012 from the University of Milano. She is currently a post-Doc fellow
12 at the Institute of Molecular Recognition Chemistry of the National Research Council of Italy where
13 she works on the design, synthesis and characterization of new polymers for bioanalytical
14 applications in the framework of several international collaborative projects. Her research activity is
15 reported in more than 15 papers on international peer-reviewed journals.

16 **Marina Cretich** graduated in Biological Science, specialty Molecular Biology at University of Milano
17 in 1998. In 2003 she has been appointed Research Scientist at the Institute of Molecular
18 Recognition Chemistry of the National Research Council of Italy where she works on the
19 development of new biochemical research methods in the microscale for diagnosis and monitoring.
20 She has been responsible of national research contracts and staff scientist in several EC funded
21 projects. Her scientific activity, documented by more than 40 articles on peer reviewed journals,
22 covers the field of microarrays, microchip electrophoresis and microfluidics.

23 **Marcus Swann** (CChem, MRSC) is Chief Scientific Officer for Farfield Group Ltd., having originally
24 joined as a post-doctoral researcher in 1999. Marcus is a physical chemist, obtaining his PhD from
25 the University of Bristol in 1991, studying conducting polymers with the electrochemical Quartz
26 Crystal Microbalance. Since then he has undertaken research at the Universities of Durham
27 (Physics) and Glasgow (Bioelectronics, Electrical Engineering) and has worked with a wide range
28 of surface analytical methods. In the last 13 years he has developed the application of the Dual
29 Polarisation Interferometry waveguide technique in areas ranging from surface science through to
30 protein characterisation and molecular interactions.

31 **Kristinn B. Gylfason** is an assistant professor of Micro and Nanosystems at the KTH Royal
32 Institute of Technology, Stockholm, Sweden. He received the PhD degree in Electrical Engineering
33 from KTH in 2010, and the BS and MS degrees in Electrical Engineering from the University of
34 Iceland in 2001 and 2003, respectively. From 2003 through 2005 he was a research engineer at
35 Lyfjathroun Biopharmaceuticals, Iceland, and from 2010 until 2014 he was a researcher at KTH.
36 During spring 2013 Kristinn was a visiting post-doctoral scholar at the Photonics Group, Ghent
37 University, Belgium. His research involves photonic sensors for biomedical applications.

38 **Tormod Volden** received the Ingénieur Diplômé degree in engineering physics from Institut
39 National des Sciences Appliquées, Toulouse, France in 1995 and worked as a staff engineer at the
40 Norwegian Radium Hospital, Oslo, Norway. From 2000 he was a research assistant at the Physical
41 Electronics Laboratory of ETH Zurich and in 2005 received the PhD degree on CMOS-integrated
42 sensors for atomic force microscopy and biochemical detection. He is since developing microfluidic
43 actuators for the company Osmotex and from 2010 for CSEM (both in Alpnach, Switzerland) in the
44 field of liquid handling and microfluidics.

45 **Marcella Chiari** graduated in Chemistry and Pharmaceutical Techniques at the Istituto di Chimica
46 Organica, Facoltà di Medicina, Università di Milano in 1982. She received the Diploma in Clinical
47 Biochemistry, Università di Milano in 1990. Since 1992 she has been Senior Researcher at the
48 ICRM, CNR, where she leads the laboratory "Development of Analytical Microsystems". Her
49 research activity is documented by more than 100 publications and several patents. She has been

1 a contractor of the EC in the framework of different projects and responsible for several national
2 research programs.

3 **Daniel Hill** gained silicon fabrication experience at Philips Semiconductors following a PhD in
4 semiconductor materials (University of Liverpool) before returning to research. Since 2006 he has
5 worked in biophotonics, being awarded the FP7 InTopSens, FP7 Positive and FP7 CanDo projects
6 as well as coordinating the FP6 SABIO project. In 2011 he joined the UMDO group (University of
7 Valencia) focussing on the nanostructuring of photonic and plasmonic materials for novel matter
8 and electromagnetic wave interaction controls to add functionality in optical biosensors. A member
9 of the IEEE, SPIE, and IOP, and a Chartered Physicist, he regularly contributes to International
10 Journals and Conferences.

11

12 References

- 13 1. X. Fan, I. M. White, S. I. Shopova, H. Zhu, J. D. Suter, and Y. Sun, Sensitive optical biosensors for
14 unlabeled targets: A review, *Anal. Chim. Acta*, vol. 620, no. 1/2, pp. 8–26, Jul. 2008. [Online]. Available:
15 <http://www.sciencedirect.com/science/article/pii/S0003267008009343>
- 16 2. D. Hill, Advances in nanophotonic sensing technologies during three international label-free lab-on-chip
17 projects, [*BioNanoScience*, vol. 1, pp. 162–172, 2011, DOI:10.1007/s12668-011-0026-1. [Online].
18 Available: <http://dx.doi.org/10.1007/s12668-011-0026-1>
- 19 3. F. S. Ligler, Perspective on optical biosensors and integrated sensor systems, *Anal. Chem.*, vol. 81, no. 2,
20 pp. 519–526, Jan. 2009. [Online]. Available: <http://pubs.acs.org/doi/abs/10.1021/ac8016289>
- 21 4. A. Brecht and G. Gauplitz, *Biosensors and Bioelectronics* 10 (1995) 923-936
- 22 5. M.C. Estevez, M. Alvarez, L.M. Lechuga “Integrated optical devices for lab-on-a-chip biosensing
23 applications” *Laser & Photon. Rev.* Vol. 6(4), pp. 463-487 (2012).
- 24 6. T.D. Lazzara, I. Mey, C. Steinem, A. Janshoff, “Benefits and limitations of porous substrates as
25 biosensors for protein adsorption” *Anal. Chem.*, Vol. 83(14), pp. 5624-5630 (2011).
- 26 7. M.M. Oroscio, C. Pacholski, M.J. Sailor “Real-time monitoring of enzyme activity in a mesoporous silicon
27 double layer”, *Nat. Nanotechnol.*, Vol. 4, pp. 255-258 (2009).
- 28 8. C.K. Tsang, T.L. Kelly, M.J. Sailor, Y.Y. Li, “Highly Stable Porous Silicon–Carbon Composites as Label-
29 Free Optical Biosensors” *ACS Nano* Vol. 6, pp. 10546-10554 (2012).
- 30 9. S.D. Alvarez, C.P. Li, C.E. Chiang, I.K. Schuller, M.J. Sailor, “A Label-Free Porous Alumina
31 Interferometric Immunosensor” *ACS Nano* Vol. 3, pp. 3301-3307 (2009).
- 32 10. T. Kumeria, M.D. Kurkuri, K.R. Diener, L. Parkinson, D. Losic, “Label-free reflectometric interference
33 microchip biosensor based on nanoporous alumina for detection of circulating tumour cells” *Biosens.*
34 *Bioelectron.*, Vol. 35(1), pp. 167-173 (2012).
- 35 11. R. M. L. van Lieshout, T. van Domburg, M. Saalmink, R. Verbeek, R. Wimberger-Friedl, M. P. van Diejen-
36 Visser and C. Punyadeera Three-Dimensional Flow-Through Protein Platform, *Anal. Chem.* 2009, 81,
37 5165–5171.
- 38 12. J. Álvarez, L. Sola, G. Platt, M. Cretich, M. Swann, M. Chiari, D. Hill, and J. Martínez-Pastor, “Real-time
39 polarimetric biosensing using macroporous alumina membranes” *Proc. SPIE* 8765, Bio-MEMS and
40 Medical Microdevices, 87650I (May 28, 2013)
- 41 13. A.A. Yanik, M. Huang, A. Artar, T.Y. Chang, H. Altug, “Integrated nanoplasmonic-nanofluidic biosensors
42 with targeted delivery of analytes” *Appl. Phys. Lett.*, Vol. 96(2), pp. 021101 (2010).
- 43 14. Y. Guo, H. Li, K. Reddy, H.S. Shelar, V.R. Nittoor, X. Fan, “Optofluidic Fabry-Perot cavity biosensor with
44 integrated flow-through micro-/nanochannels” *Appl. Phys. Lett.*, Vol. 98(4), pp. 041104 (2011).
- 45 15. G. W. Platt, F. Damin, M. J. Swann, I. Metton, G. Skorski, M. Cretich, M. Chiari, Allergen immobilisation
46 and signal amplification by quantum dots for use in a biosensor assay of IgE in serum, *Biosensors and*
47 *Bioelectronics* 52 (2014) 82–88
- 48 16. M. Mammen, G. Dahmann, G.M. Whitesides, Effective inhibitors of hemagglutination by influenza virus
49 synthesized from polymers having active ester groups — insight into mechanism of inhibition, *J. Med.*
50 *Chem.*, 38 (1995), pp. 4179–4190
- 51 17. Pirri, G ; Damin, F; Chiari, M; Bontempi, E; Depero, LE, “Characterization of a polymeric adsorbed coating
52 for DNA microarray glass slides” *ANALYTICAL CHEMISTRY* Volume: 76 Issue: 5 Pages: 1352-1358
53 (2004)
- 54 18. M. Cretich, M., Breda, D., Damin, F., Borghi, M., Sola, L., Unlu, S. M., ... & Chiari, M. (2010). Allergen
55 microarrays on high-sensitivity silicon slides. *Analytical and bioanalytical chemistry*, 398(4), 1723-1733.

- 1 19. J. Álvarez, C. Serrano, D. Hill, and J. Martínez-Pastor, "Real-time polarimetric optical sensor using
2 macroporous alumina membranes," *Opt. Lett.* Vol. 38(7), pp. 1058-1060 (2013).
- 3 20. D.A. Armbruster and Terry Pry "Limit of Blank, Limit of Detection and Limit of Quantitation" *Clin Biochem*
4 *Rev.* 29 (2008)
- 5 21. B.I. Fall, B. Eberlein-König, H. Behrendt, R. Niessner, J. Ring, and M. G. Weller, "Microarrays for the
6 Screening of Allergen-Specific IgE in Human Serum," *Analytical Chemistry*, Vol. 75, pp. 556-562 (2003).

Accepted Manuscript

BIOS

Daniel Hill gained silicon fabrication experience at Philips Semiconductors following a PhD in semiconductor materials (University of Liverpool) before returning to research. Since 2006 he has worked in biophotonics, being awarded the **FP7 InTopSens, FP7 Positive and FP7 CanDo projects as well as coordinating the FP6 SABIO project**. In 2011 he joined the UMDO group (University of Valencia) focussing on the nanostructuring of photonic and plasmonic materials for novel matter and electromagnetic wave interaction controls to add functionality in optical biosensors. A member of the IEEE, SPIE, and IOP, and a Chartered Physicist, he regularly contributes to International Journals and Conferences.

Marcus Swann (CChem, MRSC) is Chief Scientific Officer for Farfield Group Ltd., having originally joined as a post-doctoral researcher in 1999. Marcus is a physical chemist, obtaining his PhD from the University of Bristol in 1991, studying conducting polymers with the electrochemical Quartz Crystal Microbalance. Since then he has undertaken research at the Universities of Durham (Physics) and Glasgow (Bioelectronics, Electrical Engineering) and has worked with a wide range of surface analytical methods. In the last 13 years he has developed the application of the Dual Polarisation Interferometry waveguide technique in areas ranging from surface science through to protein characterisation and molecular interactions.

Kristinn B. Gylfason is an assistant professor of Micro and Nanosystems at the KTH Royal Institute of Technology, Stockholm, Sweden. He received the PhD degree in Electrical Engineering from KTH in 2010, and the BS and MS degrees in Electrical Engineering from the University of Iceland in 2001 and 2003, respectively. From 2003 through 2005 he was a research engineer at Lyfjathroun Biopharmaceuticals, Iceland, and from 2010 until 2014 he was a researcher at KTH. During spring 2013 Kristinn was a visiting post-doctoral scholar at the Photonics Group, Ghent University, Belgium. His research involves photonic sensors for biomedical applications.

Marcella Chiari graduated in Chemistry and Pharmaceutical Techniques at the Istituto di Chimica Organica, Facoltà di Medicina, Università di Milano in 1982. She received the Diploma in Clinical Biochemistry, Università di Milano in 1990. Since 1992 she has been Senior Researcher at the ICRM, CNR, where she leads the laboratory "Development of Analytical Microsystems". Her research activity is documented by more than 100 publications and several patents. She has been a contractor of the EC in the framework of different projects and responsible for several national research programs.

Marina Cretich graduated in Biological Science, specialty Molecular Biology at University of Milano in 1998. In 2003 she has been appointed Research Scientist at the Institute of Molecular Recognition Chemistry of the National Research Council of Italy where she works on the development of new biochemical research methods in the microscale for diagnosis and monitoring. She has been responsible of national research contracts and staff scientist in several EC funded projects. Her scientific activity, documented by more than 40 articles on peer reviewed journals, covers the field of microarrays, microchip electrophoresis and microfluidics.

Laura Sola received the M.S. degree in Chemistry and Pharmaceutical Techniques in 2008 and the PhD in Drug Chemistry in 2012 from the University of Milano. She is currently a post-Doc fellow at the Institute of Molecular Recognition Chemistry of the National Research Council of Italy where she works on the design, synthesis and characterization of new polymers for bioanalytical applications in the framework of several international collaborative projects. Her research activity is reported in more than 15 papers on international peer-reviewed journals.

Tormod Volden received the Ingénieur Diplômé degree in engineering physics from Institut National des Sciences Appliquées, Toulouse, France in 1995 and worked as a staff engineer at

the Norwegian Radium Hospital, Oslo, Norway. From 2000 he was a research assistant at the Physical Electronics Laboratory of ETH Zurich and in 2005 received the PhD degree on CMOS-integrated sensors for atomic force microscopy and biochemical detection. He is since developing microfluidic actuators for the company Osmotex and from 2010 for CSEM (both in Alpnach, Switzerland) in the field of liquid handling and microfluidics.

Jésus Álvarez Álvarez has a Degree in Telecommunications Engineering from the Polytechnical University of Valencia (UPV), with a final year project 'Design and Simulation of photonic sensors based on resonant rings' in the FP6 SABIO project. He then successfully completed a Masters in Technology, Systems and Communication Networks (UPV) with the thesis 'Modeling and Assessing an Energy-Aware Power-Supply Wireless Sensor Nodes for the TUHH (Hamburg University of Technology)'. In 2013 he successfully defended his PhD thesis 'Development of a polarimetric based optical biosensor using a free standing porous membrane' at UMDO (University of Valencia) from work performed in the FP7 Positive project.

Accepted Manuscript